CRISPR THERAPEUTICS AG — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$4M
R&D
$285M
D&A
$19M
Operating Income
$-665M
EBITDA
$-645M
Interest Expense
—
Interest Income
$104M
Other Income/Expense
$87M
Pretax Income
$-578M
Tax Provision
$4M
Net Income
$-582M
Operating Margin
-18933.6%
Net Margin
-16569.8%
Effective Tax Rate
-0.6%
Deferred Tax Assets
$65M
Deferred Tax Liabilities
$1M
DTA Valuation Allowance
$345M
Tax Credit Carryforwards
$78M
NOL Carryforwards
$241M
ETR (Continuing Operations)
-0.6%
ETR Federal Statutory
11.9%
ETR State + Local (pp)
1.1%
ETR Foreign Differential (pp)
-1.0%
Operating Lease Cost
$24M
Revenue YoY Variation
-90.6%
Income YoY Variation
-42.4%